About Congestive Heart Failure Drugs
Congestive heart failure is a serious and complex condition in which the heart muscles are either damaged or have to work too hard. Although the heart beats, the damaged heart muscles are too weak to pump sufficient oxygen-rich blood to and from the body. ACE inhibitors/ARB antagonists, beta-adrenergic receptor blocking agents, diuretics, and inotropic drugs are the medications available for the treatment of congestive heart failure.
TechNavio's analysts forecast the Global Congestive Heart Failure Drugs market to grow at a CAGR of 9.47 percent over the period 2014-2019.
Covered in this Report
This report covers the present scenario and the growth prospects of the Global Congestive Heart Failure Drugs market for the period 2015-2019. To calculate the market size, the report considers the revenue generated from the sales of approved drugs and generics used in the treatment of congestive heart failure that are available in the market. The Global Congestive Heart Failure Drugs market can be divided into four segments: ACE Inhibitors/ARB Antagonists, Beta-adrenergic Receptor Blocking Agents, Diuretics, and Inotropic Drugs/Vasodilators.
TechNavio's report, the Global Congestive Heart Failure Drugs Market 2015-2019, has been prepared based on an in-depth market analysis with inputs from industry experts. The report covers the Americas, and the APAC and EMEA regions; it also covers the Global Congestive Heart Failure Drugs market landscape and its growth prospects in the coming years. The report also includes a discussion of the key vendors operating in this market.
Key Regions
• Americas
• APAC
• EMEA
Key Vendors
• AstraZeneca
• Bristol-Myers Squibb
• GSK
• Merck & Co.
• Mylan
• Novartis
• Pfizer
• Sanofi
• Valeant Pharmaceuticals
Other Prominent Vendors
• Bayer
• Bioheart
• Boehringer Inhelheim
• Takeda Pharmaceutical
• Teva Pharmaceutical Industries
Market Driver
• Increase in Aging Population
• For a full, detailed list, view our report
Market Challenge
• Weak Pipeline
• For a full, detailed list, view our report
Market Trend
• Increase in Awareness
• For a full, detailed list, view our report
Key Questions Answered in this Report
• What will the market size be in 2019 and what will the growth rate be?
• What are the key market trends?
• What is driving this market?
• What are the challenges to market growth?
• Who are the key vendors in this market space?
• What are the market opportunities and threats faced by the key vendors?
• What are the strengths and weaknesses of the key vendors?
01. Executive Summary
02. List of Abbreviations
03. Scope of the Report
03.1 Market Overview
03.2 Product Offerings
03.2.1 Product Profiles
04. Market Research Methodology
04.1 Market Research Process
04.2 Research Methodology
05. Introduction
06. Market Landscape
06.1 Market Overview
06.2 Market Size and Forecast
06.3 Five Forces Analysis
07. Market Segmentation by Therapeutic Class
08. Late Stage Pipeline Molecules
09. Geographical Segmentation
09.1 Congestive Heart Failure Drugs Market in Americas
09.1.1 Market Size and Forecast
09.2 Congestive Heart Failure Drugs Market in Europe
09.2.1 Market Size and Forecast
09.3 Congestive Heart Failure Drugs Market in Asia
09.3.1 Market Size and Forecast
09.4 Congestive Heart Failure Drugs Market in ROW
09.4.1 Market Size and Forecast
10. Buying Criteria
11. Market Growth Drivers
12. Drivers and their Impact
13. Market Challenges
14. Impact of Drivers and Challenges
15. Market Trends
16. Trends and their Impact
17. Vendor Landscape
17.1 Competitive Scenario
17.1.1 Key News
17.1.2 Mergers and Acquisitions
17.2 Market Share Analysis 2013
17.3 Other Prominent Vendors
18. Key Vendor Analysis
18.1 AstraZeneca plc
18.1.1 Key Facts
18.1.2 Business Overview
18.1.3 Business Segmentation by Revenue 2013
18.1.4 Business Segmentation by Revenue 2011-2013
18.1.5 Sales by Geography
18.1.6 Business Strategy
18.1.7 Key Developments
18.1.8 SWOT Analysis
18.2 Bristol-Myers Squibb Co.
18.2.1 Key Facts
18.2.2 Business Overview
18.2.3 Key Product Offerings
18.2.4 Revenue by Geography
18.2.5 Business Strategy
18.2.6 Key Information
18.2.7 SWOT Analysis
18.3 GlaxoSmithKline
18.3.1 Key Facts
18.3.2 Business Overview
18.3.3 Business Segmentation
18.3.4 Business Segmentation by Revenue 2012 and 2013
18.3.5 Sales by Geography
18.3.6 Pipeline Products
18.3.7 Business Strategy
18.3.8 Key Information
18.3.9 SWOT Analysis
18.4 Merck & Co. Inc.
18.4.1 Key Facts
18.4.2 Business Overview
18.4.3 Business Segmentation by Revenue 2013
18.4.4 Business Segmentation by Revenue 2012 and 2013
18.4.5 Sales by Geography
18.4.6 Business Strategy
18.4.7 Key Developments
18.4.8 SWOT Analysis
18.5 Mylan
18.5.1 Key Facts
18.5.2 Business Overview
18.5.3 Business Segmentation by Revenue 2013
18.5.4 Business Segmentation by Revenue 2011-2013
18.5.5 Geographical Segmentation by Revenue 2013
18.5.6 Business Strategy
18.5.7 Recent Developments
18.5.8 SWOT Analysis
18.6 Novartis AG
18.6.1 Key Facts
18.6.2 Business Description
18.6.3 Business Segmentation
18.6.4 Revenue by Business Segmentation
18.6.5 Revenue Comparison 2012 and 2013
18.6.6 Sales by Geography
18.6.7 Business Strategy
18.6.8 Key Developments
18.6.9 SWOT Analysis
18.7 Pfizer
18.7.1 Key Facts
18.7.2 Business Overview
18.7.3 Business Segmentation by Revenue 2013
18.7.4 Business Segmentation by Revenue 2012 and 2013
18.7.5 Geographical Segmentation by Revenue
18.7.6 Business Strategy
18.7.7 Key Developments
18.7.8 SWOT Analysis
18.8 Sanofi SA
18.8.1 Key Facts
18.8.2 Business Description
18.8.3 Business Segmentation
18.8.4 Revenue by Business Segmentation
18.8.5 Revenue Comparison 2012 and 2013
18.8.6 Sales by Geography
18.8.7 Business Strategy
18.8.8 Key Developments
18.8.9 SWOT Analysis
18.9 Valeant Pharmaceuticals International
18.9.1 Key Facts
18.9.2 Business Overview
18.9.3 Business Segmentation by Revenue 2013
18.9.4 Business Segmentation by Revenue 2012 and 2013
18.9.5 Sales by Geography
18.9.6 Business Strategy
18.9.7 Key Developments
18.9.8 SWOT Analysis
19. Other Reports in this Series
List of Exhibits
Exhibit 1: Market Research Methodology
Exhibit 2: Global Congestive Heart Failure Drugs Market 2014-2019 (US$ billion)
Exhibit 3: Global Congestive Heart Failure Drugs Market Segmentation by Therapeutic Class
Exhibit 4: Congestive Heart Failure: Clinical Developmental Pipeline
Exhibit 5: Global Congestive Heart Failure Drugs Market by Geographical Segmentation 2014
Exhibit 6: Congestive Heart Failure Drugs market in Americas 2014-2019 (US$ billion)
Exhibit 7: Congestive Heart Failure Drugs market in Europe 2014-2019 (US$ billion)
Exhibit 8: Congestive Heart Failure Drugs market in Asia 2014-2019 (US$ billion)
Exhibit 9: Congestive Heart Failure Drugs Market in ROW 2014-2019 (US$ billion)
Exhibit 10: Global Congestive Heart Failure Drugs Market by Geographical Segmentation 2014-2019 (in Percent)
Exhibit 11: Global Congestive Heart Failure Drugs Market by Geographical Segmentation 2014-2019 (in Revenue)
Exhibit 12: Estimated Prevalence of Congestive Heart Failure in Different Age-group (years) in the US
Exhibit 13: Age-specific Male Incidence Rates (per 1000 man years) in Congestive Heart Failure
Exhibit 14: Age-specific Female Incidence Rates (per 1000 woman-years) in Congestive Heart Failure
Exhibit 15: AstraZeneca Year on Year Sales Comparison 2010-2013 (US$ billion)
Exhibit 16: GSK Year on Year Sales Comparison 2010-2013 (US$ billion)
Exhibit 17: GSK's Total Global Sales of Medicines by Therapeutic Classes 2013 (percentage)
Exhibit 18: GSK Coreg Year on Year Sales Comparison 2010-2013 (US$ billion)
Exhibit 19: Merck & Co. Year on Year Sales Comparison 2010-2013 (US$ billion)
Exhibit 20: Mylan Year on Year Sales Comparison 2010-2013 (US$ billion)
Exhibit 21: Novartis Diovan Year on Year Sales Comparison 2010-2013 (US$ billion)
Exhibit 22: Novartis Year on Year Sales Comparison 2010-2013 (US$ billion)
Exhibit 23: Pfizer Year on Year Sales Comparison 2010-2013 (US$ billion)
Exhibit 24: Sanofi Year on Year Sales Comparison 2010-2013 (US$ billion)
Exhibit 25: Valeant Pharmaceuticals Year on Year Sales Comparison 2010-2013 (US$ billion)
Exhibit 26: Valeant Pharmaceuticals Revenue Breakdown by Product Segments
Exhibit 27: AstraZeneca plc: Business Segmentation by Revenue 2013
Exhibit 28: AstraZeneca plc: Business Segmentation by Revenue 2011-2013 (US$ million)
Exhibit 29: AstraZeneca plc: Sales by Geography 2013
Exhibit 30: Bristol-Myers Squibb Co.: Key Product Offerings (Based on Therapeutic Areas)
Exhibit 31: Bristol-Myers Squibb Co.: Revenue by Geographical Segmentation 2013
Exhibit 32: GlaxoSmithKline: Business Segmentation 2013
Exhibit 33: GlaxoSmithKline: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 34: GlaxoSmithKline: Sales by Geography 2013
Exhibit 35: GlaxoSmithKline: Pipeline Products 2013
Exhibit 36: Merck & Co. Inc.: Business Segmentation by Revenue 2013
Exhibit 37: Merck & Co. Inc.: Business Segmentation by Revenue 2012 and 2013 (US$ billion)
Exhibit 38: Merck & Co. Inc.: Sales by Geography 2013
Exhibit 39: Global Congestive Heart Failure Drugs Market: Business Segmentation by Revenue 2013
Exhibit 40: Global Congestive Heart Failure Drugs Market: Business Segmentation by Revenue 2011-2013 (US$ billion)
Exhibit 41: Global Congestive Heart Failure Drugs Market: Geographical Segmentation by Revenue 2013
Exhibit 42: Novartis AG: Business Segmentation
Exhibit 43: Novartis AG: Revenue by Business Segmentation 2013
Exhibit 44: Novartis AG: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 45: Novartis AG: Revenue by Geographical Segmentation 2013
Exhibit 46: Pfizer: Business Segmentation by Revenue 2013
Exhibit 47: Pfizer: Business Segmentation by Revenue 2012 and 2013
Exhibit 48: Pfizer: Geographical Segmentation by Revenue 2013
Exhibit 49: Sanofi SA: Business Segmentation
Exhibit 50: Sanofi SA: Revenue by Business Segmentation 2013
Exhibit 51: Sanofi SA: Revenue by Business Segmentation 2012 and 2013 (US$ million)
Exhibit 52: Sanofi SA: Sales Revenue by Geographical Segmentation 2013
Exhibit 53: Valeant Pharmaceuticals International: Business Segmentation by Revenue 2013
Exhibit 54: Valeant Pharmaceuticals International: Business Segmentation by Revenue 2012 and 2013 (US$ million)
Exhibit 55: Valeant Pharmaceuticals International: Sales by Geography 2013
